CarGurus Announces Third Quarter 2017 Financial Results
Nov 14, 2017 21:02 pm UTC| Business
Total revenue of $83.0 million, an increase of 56% year-over-yearGAAP operating income of $2.9 million; Non-GAAP operating income of $2.9 millionGAAP net income of $2.4 million; Non-GAAP net income of $2.2 millionAdjusted...
StoneMor Partners L.P. Issues Update on Sales Team Development
Nov 14, 2017 21:02 pm UTC| Business
TREVOSE, Pa., Nov. 14, 2017 -- StoneMor Partners L.P. (NYSE:STON) (“StoneMor” or the “Partnership”) today provided additional data on the ongoing restructuring of its sales force. Total salespeople within the...
Aptevo Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference
Nov 14, 2017 21:02 pm UTC| Business
SEATTLE, Nov. 14, 2017 -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the 29th...
Giga-tronics Reports Second Quarter FY 2018 Results
Nov 14, 2017 21:02 pm UTC| Business
DUBLIN, Calif., Nov. 14, 2017 -- Giga-tronics Incorporated (OTCQB:GIGA) (the “Company”) reported today net sales for the second quarter of fiscal 2018 of $2.2 million, a 49% decrease as compared to $4.4 million for the...
TSS, Inc. Reports Third Quarter 2017 Results
Nov 14, 2017 21:02 pm UTC| Business
ROUND ROCK, Texas, Nov. 14, 2017 -- TSS, Inc. (Other OTC:TSSI), a data center and mission critical facilities and technology services company, reported results for its third quarter ended September 30, 2017. Third...
IsoRay Announces First Quarter Fiscal 2018 Financial Results
Nov 14, 2017 21:02 pm UTC| Business
RICHLAND, Wash., Nov. 14, 2017 -- IsoRay, Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and...
Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G
Nov 14, 2017 21:01 pm UTC| Business
- Greater than 50% improvement in proteinuria (albumin to creatinine ratio) after 14 days of oral dosing with ACH-4471 - - Improvement in complement alternative pathway biomarkers observed - NEW HAVEN,...